The clinical effect of phorbol ester on patients with hematological diseases in the period of myelosuppression after chemotherapy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100050523

Enrollment

Unknown

Registered

2021-08-28

Start date

2021-09-01

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood system diseases

Interventions

Experimental group:Use phorbol ester

Control group:Symptomatic and supportive treatment

Eligibility

Sex/Gender

All

Age

10 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. After chemotherapy in patients with hematological diseases; 2. Aged 10 to 65 years; 3. Liver function: total protein>60g/L, of which albumin>40g/L; 4. Renal function: BUN 3.2-6.1 mmol/L, whole blood creatinine 88.4-176.8 µmol/L, serum creatinine: male 53-106 µmol/L, female 44-97 µmol/L.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
cytokine;Lymphocyte subsets;blood routine examination;Bone marrow cytology examination;Blood coagulation function examination;Liver function test;Kidney function test ;	—

Countries

China

Contacts

Public ContactSong Qinglin

People's Hospital of Jiaozuo City

595502167@qq.com+86 13343918658

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026